Recurrent subcutaneous sweet’s disease in a myelofibrosis patient treated with ruxolitinib before allogeneic stem cell transplantation

Teppei Sakoda, Yoko Kanamitsu, Yasuo Mori, Kensuke Sasaki, Etsuko Yonemitsu, Konosuke Nagae, Goichi Yoshimoto, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Toshihiro Miyamoto, Masutaka Furue, Hiromi Iwasaki, Koichi Akashi

研究成果: Contribution to journalArticle

4 被引用数 (Scopus)

抄録

Allogeneic hematopoietic stem cell transplantation (allo-SCT) has a curative potential for myelofibrosis (MF) patients; however, its association with a high therapy-related mortality (TRM) remains a big obstacle that needs to be overcome. Ruxolitinib (RUXO), a novel JAK1/2 inhibitor, can be used as a bridging therapy until allo-SCT can be performed to reduce TRM. We herein report a RUXO-treated MF patient who developed recurrent subcutaneous Sweet’s disease (SSD) that was successfully treated by the administration of systemic glucocorticoids. We performed allo-SCT as previously scheduled, resulting in a good clinical course without deterioration of SSD. RUXO administration, as well as MF itself, might therefore sometimes cause this rare non-infectious event.

本文言語英語
ページ(範囲)2481-2485
ページ数5
ジャーナルInternal Medicine
56
18
DOI
出版ステータス出版済み - 2017

All Science Journal Classification (ASJC) codes

  • Internal Medicine

フィンガープリント 「Recurrent subcutaneous sweet’s disease in a myelofibrosis patient treated with ruxolitinib before allogeneic stem cell transplantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル